Actual role and perspectives in the treatment of hormone refractory prostatic cancer

@inproceedings{Silvestris2017ActualRA,
  title={Actual role and perspectives in the treatment of hormone refractory prostatic cancer},
  author={Nicola Silvestris and Vito Lorusso},
  year={2017}
}
Nicola Silvestris Unità operativa di Oncologia Medica Centro Oncologico “Giorgio Porfiri” Ospedale Santa Maria Goretti Via Canova 04100 Latina Tel. 0773 6553842 e-mail: nicolasilvestris@virgilio.it Il blocco androgenico rappresenta il trattamento standard del carcinoma prostatico metastatico al momento della diagnosi. Sfortunatamente quasi tutti i pazienti sviluppano nel tempo una malattia androgeno-indipendente (ormonoresistente) che comporta un progressivo deterioramento delle condizioni… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 67 REFERENCES

Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2004

Chemotherapy for patients with hormone-refractory prostate cancer.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2004

Mechani - sms of androgen - refractory prostate cancer

HI Scher, M Mazumdar, NK Kelly
  • N Engl J Med
  • 2004

Randomi - zed phase III study of i . v . vinorel - bine plus hormonotherapy versus hormonotherapy alone in hormone - refractory prostate cancer

CA Perry, D McTavish
  • Ann Oncol
  • 2004

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004

A phase II study of oblimersen disodium and docetaxel in patients with metastatic hormone - refractory prostate cancer

KN Chi, RN Murray, ME Gleave
  • Proc Am Soc Clin Oncol
  • 2003

Similar Papers

Loading similar papers…